ReviewClinical reviews in allergy & immunology2025
Inflammation and Immune Pathways in Myopia: An Overview on Pathomechanisms and Treatment Prospects.
Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Application of nanozyme-based drug delivery systems in the treatment of ROS-related ophthalmic diseases.International journal of pharmaceutics: X · 2026Review
- Review
- The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics.Investigative ophthalmology & visual science · 2026Review
- Anthocyanins as Adjunctive Dietary Modulators of the Gut-Eye Axis: Bioavailability, Biotransformation, and Implications for Ocular Health.Foods (Basel, Switzerland) · 2026Review
- Vitamin DBiomolecules · 2026Article
- Beneficial Effects of Natural Bioactive Compounds on Eye Health: A Narrative Review.International journal of molecular sciences · 2026Review
- Cytomegalovirus Infection of the Anterior Segment: Corneal Endotheliitis and Secondary Glaucoma.Pathogens (Basel, Switzerland) · 2026Review
- Gene expression and machine learning techniques uncover corneal biomarkers associated with oxidative stress in the myopia progression.Scientific reports · 2026Article
- Relationship between choroidal thickness changes and macrophage polarization in high myopia.Frontiers in medicine · 2026Review
- Lipid-Based Nanocarriers for Curcumin Delivery: A Promising Strategy in The Management of Inflammatory Diseases.International journal of nanomedicine · 2026Review
- 92-Plex Inflammatory Proteomic Signatures in Aqueous Humor of High Myopia and Candidate Biomarkers.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Pyroptosis-associated inflammasome activation contributes to scleral remodeling in experimental myopia.International journal of ophthalmology · 2026Article
- Potential Ferroptosis-Related Genes and Immune Infiltration in Form-Deprivation Myopia: An Integrative Bioinformatics and in vitro Validation Study.International journal of general medicine · 2026Article
- Cellular Biological Basis and Novel Breakthroughs in the Pathogenesis of Myopia - A Narrative Review.International journal of general medicine · 2026Review
- Hypoxia-induced OPN5 expression is associated with matrix-preserving responses in human scleral fibroblasts.Frontiers in neuroscience · 2026Article
- A TabPFN-based prediction system for refractive error and dry eye comorbidity: a retrospective study using large-scale real-world data.Frontiers in cell and developmental biology · 2026Article
- Myo-inflam: a mini review on inflammatory pathways driving scleral remodeling and axial elongation.Frontiers in immunology · 2026Review
- Sex-specific associations between gut microbiota and myopia in adolescents: a clinical predictive modeling study.Frontiers in cellular and infection microbiology · 2026Article
- Correlation Between Myopia Degree and Postoperative Dry Eye Disease in Keratorefractive Lenticule Extraction Surgery.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Myopia represents a growing global public health challenge, characterized by increasing prevalence and associated complications such as myopic macular degeneration and retinal detachment. Although genetic and environmental factors are well-recognized contributors, emerging evidence supports a pathological link between inflammation and myopia progression. Epidemiological studies indicate a higher incidence of myopia among individuals with systemic or ocular inflammatory conditions. Inflammation perturbs the ocular immune microenvironment by upregulating pro-inflammatory cytokines and matrix metalloproteinase-2, thereby accelerating extracellular matrix (ECM) degradation and scleral remodeling, which culminates in axial elongation. Conversely, excessive axial elongation in high myopia triggers choroidal microvascular dysfunction, tissue hypoxia, and disruption of the blood-retinal barrier, leading to elevated inflammatory cytokines in the aqueous humor and vitreous, thereby raising the possibility of a self-perpetuating loop. Anti-inflammatory agents, including diacerein, resveratrol, and lactoferrin, have demonstrated therapeutic potential in experimental models by modulating inflammatory pathways, reducing pro-inflammatory cytokines, and preserving ECM integrity. However, their clinical efficacy and long-term safety require further validation. Elucidating the complex interplay between inflammation and myopia is pivotal for the development of targeted interventions, moving the focus of myopia management beyond optical correction towards disease-modifying strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.